Adalimumab
Treatment for Crohns Disease
Typical Dosage: 160 mg SC at week 0, 80 mg SC at week 2, then 40 mg SC every other week
Effectiveness
75%
Safety Score
45%
Clinical Trials
124
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
160 mg SC at week 0, 80 mg SC at week 2, then 40 mg SC every other week
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
35(Treat 35 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$12,000
Monitoring:$1,150
Side Effect Mgmt:$750
Total Annual:$13,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$23,966
Cost per Remission
$36,579
Adalimumab Outcomes
for Crohns Disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+58%
Remission Rate
+38%
Common Side Effects
Injection site reactions
+15%
Upper respiratory tract infection
+25%
Headache
+15%
Serious infections
+4%
Malignancy (lymphoma, skin cancer)
+0.5%
Sources:
Active Clinical Trials
1 active trial recruiting for Adalimumab in Crohns Disease
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06180382RECRUITINGPHASE4
220 participants
INTERVENTIONAL
Le Kremlin-Bicêtre, France +11 more
Started: Oct 31, 2024
Completed Clinical Trials
18 completed trials for Adalimumab in Crohns Disease
Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
NCT01564823COMPLETEDPHASE3
86 participants
INTERVENTIONAL
Badalona, Spain +21 more
Started: Jun 1, 2012
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
NCT00409682COMPLETEDPHASE3
192 participants
INTERVENTIONAL
Los Angeles, United States +44 more
Started: Apr 1, 2007
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
NCT00409617COMPLETEDPHASE3
945 participants
INTERVENTIONAL
Graz, Austria +188 more
Started: Dec 1, 2006
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
NCT03890445COMPLETED
63 participants
OBSERVATIONAL
Innsbruck, Austria +17 more
Started: Jun 24, 2019
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
NCT01958827COMPLETEDPHASE3
28 participants
INTERVENTIONAL
Started: Sep 1, 2013
Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
NCT00348283COMPLETEDPHASE3
135 participants
INTERVENTIONAL
Atlanta, United States +20 more
Started: Aug 1, 2006
Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study
NCT02450513COMPLETED
30 participants
OBSERVATIONAL
Leuven, Belgium +1 more
Started: Mar 1, 2012
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
NCT02185014COMPLETEDPHASE3
252 participants
INTERVENTIONAL
Started: Aug 12, 2014
Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
NCT00686374COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Started: May 1, 2008
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
NCT00445939COMPLETEDPHASE2, PHASE3
90 participants
INTERVENTIONAL
Aichi, Japan +17 more
Started: Feb 1, 2007
Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial
NCT02256462COMPLETEDPHASE4
82 participants
INTERVENTIONAL
Petah Tikva, Israel
Started: May 1, 2015
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
NCT02871635COMPLETEDPHASE3
147 participants
INTERVENTIONAL
Jacksonville, United States +91 more
Started: Sep 28, 2016
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
NCT02148718COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Started: Jun 1, 2014
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
NCT00195715COMPLETEDPHASE3
777 participants
INTERVENTIONAL
Huntsville, United States +110 more
Started: Sep 1, 2004
Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease
NCT02539849COMPLETEDNA
38 participants
INTERVENTIONAL
Santiago de Compostela, Spain +4 more
Started: Dec 1, 2014
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
NCT02015793COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Started: Dec 1, 2013
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
NCT00427921COMPLETEDPHASE3
304 participants
INTERVENTIONAL
Abbott Park, United States
Started: Jan 1, 2007
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
NCT02499783COMPLETEDPHASE3
205 participants
INTERVENTIONAL
Started: Aug 17, 2015
Showing 20 of 125 total trials